Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis

Circ Heart Fail. 2012 Jul 1;5(4):e68-70. doi: 10.1161/CIRCHEARTFAILURE.112.966804.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antibiotics, Antineoplastic / adverse effects
  • Cardiomyopathies / diagnosis
  • Cardiomyopathies / etiology
  • Cardiomyopathies / physiopathology
  • Cardiomyopathies / therapy*
  • Doxorubicin / adverse effects
  • Drug Monitoring / methods
  • Eptifibatide
  • Female
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Gastrointestinal Hemorrhage / chemically induced
  • Heart-Assist Devices / adverse effects*
  • Humans
  • International Normalized Ratio
  • Male
  • Myocardial Ischemia / complications
  • Peptides / adverse effects
  • Peptides / therapeutic use*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Thrombosis / blood
  • Thrombosis / diagnosis
  • Thrombosis / drug therapy*
  • Thrombosis / etiology
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Ventricular Function, Left

Substances

  • Antibiotics, Antineoplastic
  • Fibrinolytic Agents
  • Peptides
  • Platelet Aggregation Inhibitors
  • Doxorubicin
  • Eptifibatide